Ethyl Icosa-11,14-dienoate | 103213-62-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ethyl Icosa-11,14-dienoate
• CAS: 103213-62-3
• 化学式: C₂₂H₄₀O₂
• 分子量: 336.6
• InChiKey: PYVCCFLKWCNDQZ-UHFFFAOYSA-N

物化性质

• 溶解度：
  二氯甲烷；

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  24
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Multiple phase cross-linked compositions and uses thereof
  申请人：——

  公开号：US20020076443A1

  公开（公告）日：2002-06-20

  The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

  本发明涉及制备药物组合物和制备药物组合物的方法，其中药物组合物包括至少一种治疗剂物理上被包裹在交联基质中。该基质可能包括除水相外的一个或多个相，例如固体和/或油相。本发明的基质具有至少一个体内控制释放动力学特性，并且可能具有相同药物的其他特性。基质还可以包括多种治疗剂，每种附加治疗剂可能具有一个或多个体内控制释放动力学特性。
• MULTIPLE PHASE CROSS-LINKED COMPOSITIONS AND USES THEREOF
  申请人：Stein Stanley

  公开号：US20110135732A1

  公开（公告）日：2011-06-09

  The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.
• [EN] MULTIPLE PHASE CROSS-LINKED COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS RETICULEES A PHASES MULTIPLES ET UTILISATIONS DE CES DERNIERES
  申请人：UNIV NEW JERSEY MED

  公开号：WO2001097865A2

  公开（公告）日：2001-12-27

  The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.